Articles related to VACCINES

In this cross-sectional study of US adults hospitalized with COVID-19 during January 2022 to April 2022, hospitalization rates from COVID were 10.5 times higher in unvaccinated persons and 2.5 times higher in vaccinated persons with no booster dose, respectively, compared with those who had received a booster dose.

All vaccines are expected to be quadrivalent. Included in the update are expanded approval for Flucelvax Quadrivalent, administration adjustments for Afluria Quadrivalent, and higher dose vaccines for those 65 years old and older.

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.

An efficacy number that’s been widely and unquestioningly quoted by various media organizations — “85% effective” or “at least 85% effective” — is based entirely on a small study done in Africa in the 1980s that has major limitations and with “pretty weak” findings.

JAMA Network Open | Original Investigation

In this Journal Club discussion, among participants in the vaccine-CD20-vaccine cohort, 100% of participants experienced a measurable response to a third dose of a COVID-19 vaccine compared with 18% in the CD20-vaccine cohort.